Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target
E A Sausville1, D Zaharevitz, R Gussio
1Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD 20852, USA.
Pharmacology & Therapeutics
|August 24, 1999
Summary
Researchers identified NSC 664704, a novel benzodiazepine derivative, as a potential anti-cancer agent. This compound inhibits cyclin-dependent kinases (CDKs) and shows promise for treating hyperproliferative disorders.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) regulate cell cycle progression; their deregulation is linked to cancer.
- Flavopiridol inhibits CDKs but has toxicities, necessitating new therapeutic agents.
- Novel chemotypes are needed for cancer and hyperproliferative disorder treatments.
Purpose of the Study:
- To identify novel CDK inhibitors with potential therapeutic applications.
- To find alternative compounds to flavopiridol with improved safety profiles.
- To explore new lead structures for anti-cancer drug development.
Main Methods:
- Utilized computer-assisted pattern recognition (COMPARE) on in vitro anticancer drug screen data.
- Screened identified compounds for anti-CDK activity using biochemical assays.
- Investigated the mechanism of action and cell cycle effects of lead compounds.
Main Results:
- Identified NSC 664704, a benzodiazepine derivative, as a moderate inhibitor of CDK2 (IC50 0.4 microM).
- NSC 664704 demonstrated cell cycle redistribution in living cells.
- This compound serves as a candidate for further optimization based on structure-activity relationships.
Conclusions:
- NSC 664704 is a promising lead compound for developing novel CDK-targeted cancer therapies.
- Combining empirical screening with structure-based design can yield effective therapeutic agents.
- Further research on NSC 664704 may lead to treatments for cancer and hyperproliferative diseases.
Related Concept Videos
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...